Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. News
Jul 29, 2025 - globenewswire.com
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease
Jul 21, 2025 - globenewswire.com
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease
Jul 16, 2025 - globenewswire.com
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Jul 10, 2025 - globenewswire.com
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
Cognition Therapeutics, Inc. Quantitative Score
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Cognition Therapeutics, Inc. Financials
Table Compare
Compare CGTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | CGTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CGTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CGTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CGTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Cognition Therapeutics, Inc. Income
Cognition Therapeutics, Inc. Balance Sheet
Cognition Therapeutics, Inc. Cash Flow
Cognition Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Cognition Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Ms. Lisa Ricciardi | Chief Executive Officer, President & Director |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D |
| Mr. John Brendan Doyle | Chief Financial Officer |
| Ms. Anita Cornet | Head of Quality |
| Dr. Steven A. Weissman Ph.D. | Vice President & Head of CMC |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Lisa Ricciardi | Chief Executive Officer, President & Director | Female | 1960 | 951.74K |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | 1970 | 676.37K | |
| Mr. John Brendan Doyle | Chief Financial Officer | Male | 1977 | 619.94K |
| Ms. Anita Cornet | Head of Quality | Female | -- | |
| Dr. Steven A. Weissman Ph.D. | Vice President & Head of CMC | -- |
Cognition Therapeutics, Inc. Insider Trades
| Date | 29 Jul |
| Name | Caggiano Anthony |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 65000 |
| Date | 29 Jul |
| Name | Caggiano Anthony |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 20281 |
| Date | 29 Jul |
| Name | Doyle John Brendan |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 30000 |
| Date | 29 Jul |
| Name | Doyle John Brendan |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 9360 |
| Date | 29 Jul |
| Name | Ricciardi Lisa |
| Role | CEO & President |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 75000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 29 Jul | Caggiano Anthony | Chief Medical Officer | Acquired | A-Award | 65000 |
| 29 Jul | Caggiano Anthony | Chief Medical Officer | Disposed | F-InKind | 20281 |
| 29 Jul | Doyle John Brendan | Chief Financial Officer | Acquired | A-Award | 30000 |
| 29 Jul | Doyle John Brendan | Chief Financial Officer | Disposed | F-InKind | 9360 |
| 29 Jul | Ricciardi Lisa | CEO & President | Acquired | A-Award | 75000 |